ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

10,531Medicare Part D Prescriptions Filled, Including Refills

Rank: 149 out of 1171

$538K Total Retail Price of All Prescriptions

Rank: 191 out of 1171

384 Patients Receiving at Least One Drug in Part D
52%Patients 65 Years and Older
89% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Virginia
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 384 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

6% of this provider’s 384 patients filled at least one prescription for a schedule three drug, compared to an average of 8%.

Risky Drugs to Seniors

1% of this provider’s 6,831 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Virginia
AMLODIPINE BESYLATE 536 352 1 2
LISINOPRIL 481 251 2 3
SIMVASTATIN 382 205 3 1
FUROSEMIDE 366 304 4 6
OMEPRAZOLE 357 192 5 5
METOPROLOL TARTRATE 355 233 6 11
LEVOTHYROXINE SODIUM 282 220 7 4
NAMENDA 243 234 8 42
METFORMIN HCL 222 117 9 7
DONEPEZIL HCL 197 191 10 24
METOPROLOL SUCCINATE 195 121 11 17
OXYCODONE-ACETAMINOPHEN 181 108 S2 12 59
QUETIAPINE FUMARATE 153 102 13 54
OXYBUTYNIN CHLORIDE ER 145 82 14 135
WARFARIN SODIUM 128 99 15 12
HYDROCHLOROTHIAZIDE 127 81 16 9
ATORVASTATIN CALCIUM 127 57 16 10
MIRTAZAPINE 127 113 16 50
FAMOTIDINE 119 58 19 75
CITALOPRAM HBR 116 101 20 22
KLOR-CON M20 113 78 21 41
PANTOPRAZOLE SODIUM 107 85 22 29
LEVETIRACETAM 101 41 23 84
CIPROFLOXACIN HCL 89 46 24 61
GABAPENTIN 89 45 24 16
RISPERIDONE 88 64 26 77
OXYBUTYNIN CHLORIDE 87 30 27 171
CLONIDINE HCL 85 37 28 45
BENZTROPINE MESYLATE 84 53 R 29 162
ATENOLOL 81 40 30 15
NAPROXEN 80 45 31 95
LANTUS 74 27 32 46
DIGOXIN 72 50 33 68
CARBIDOPA-LEVODOPA 69 58 34 107
CLOPIDOGREL 66 63 35 35
ISOSORBIDE MONONITRATE ER 64 54 36 44
FINASTERIDE 61 52 37 88
TAMSULOSIN HCL 60 50 38 28
DOXAZOSIN MESYLATE 58 24 39 82
IBUPROFEN 58 23 39 80
BACLOFEN 56 23 41 110
HALOPERIDOL 56 37 41 176
INSULIN SYRINGE 54 24 43 71
SEROQUEL 53 31 44 120
ADVAIR DISKUS 53 31 44 51
TOPIRAMATE 52 0 46 196
PHENYTOIN SODIUM EXTENDED 51 36 47 137
CARVEDILOL 50 44 48 20
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Oct. 28, 2013.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.